Immunome Inc. (IMNM) stock
IMNMNasdaqPharmaceutical PreparationsFiscal year ends December 31
$16.78−0.40 (-2.33%)
Close on Nov 18, 2026Market cap $1.91BP/E –Yield –
Immunome revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Immunome's revenue for the twelve months ending Mar 31, 2026 was $4.02M, down 63.3% year over year. For fiscal 2025 it was $6.94M, down 23.2% from the year before.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.94M | -23.2% |
| FY2024 | Dec 31, 2024 | $9.04M | -35.5% |
| FY2023 | Dec 31, 2023 | $14.02M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2026 | Mar 31, 2026 | $0 | -100.0% |
| Q4 FY2025 | Dec 31, 2025 | $0 | -100.0% |
| Q3 FY2025 | Sep 30, 2025 | $0 | -100.0% |
| Q2 FY2025 | Jun 30, 2025 | $4.02M | +69.8% |
| Q1 FY2025 | Mar 31, 2025 | $2.93M | +184.4% |
| Q4 FY2024 | Dec 31, 2024 | $2.74M | -28.4% |
| Q3 FY2024 | Sep 30, 2024 | $2.91M | -18.4% |
| Q2 FY2024 | Jun 30, 2024 | $2.36M | -44.5% |
| Q1 FY2024 | Mar 31, 2024 | $1.03M | -56.5% |
| Q4 FY2023 | Dec 31, 2023 | $3.83M | – |
| Q3 FY2023 | Sep 30, 2023 | $3.57M | – |
| Q2 FY2023 | Jun 30, 2023 | $4.26M | – |
| Q1 FY2023 | Mar 31, 2023 | $2.36M | – |
See a number that looks wrong?